Izar
izar.ae
Actively hiring
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Knowhow and experience through their international methanol network.
News
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports...
Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a...
Read more
Report
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab' s 60 mg with induction, and significant responses were observed acr
Read more
Report
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody sonelokimab in patients with active psoriatic arthritis - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Spain: IZAR Shows Its Mettle in the Gas Sector
As the sole shipbuilding organization outside eastern Asia with a current involvement in the construction of large LNG carriers…
Read more
Report